ALNA stock $0.075 pre-market Allena Pharmaceuticals NASDAQ 04 Feb 2026: monitor

ALNA stock trades at $0.075 pre-market on NASDAQ. Volume surged to 252,311,606 shares, ranking the name among the most active in early U.S. trading. The session high reached $0.15 and the open was $0.06. Traders are watching liquidity, clinical updates, and cash runway for Allena Pharmaceuticals, Inc. as the name moves ahead of regular hours.

ALNA stock pre-market action

Allena Pharmaceuticals (ALNA) shows a pre-market price of $0.075 versus yesterday’s close of $0.0727, a change of +3.16%. The intraday low is $0.06 and the high is $0.1459, with an open at $0.0641. Reported volume is 252,311,606 shares, which explains its placement on most-active lists for this pre-market session.

Drivers behind the high trading volume

Volume spikes reflect speculative trading in low-priced biotech names and rotation into small caps. No new company press release appears in the tape, so momentum likely comes from retail flow and options activity. For market context on active biotech trading today see Reuters and sector headlines source.

ALNA stock financial and valuation snapshot

Allena operates in Healthcare, Biotechnology, and lists key metrics showing early-stage losses. EPS is -0.64 and trailing PE reads -0.12. Balance-sheet strength includes $0.92 cash per share and a current ratio of 2.11, while book value per share is $0.58. Enterprise value shows a negative figure of -29,461,000.00 reflecting low market capitalization and reported liabilities.

Liquidity, technicals and trading risks for ALNA stock

High volume can compress spreads and increase short-term liquidity for ALNA stock. The float and average volume data are thin or missing, which raises intraday volatility risk. Bid-ask swings have widened around the session high, so stop-aware traders should use limit orders and position-size carefully.

Meyka AI rates ALNA with a score out of 100 and forecast

Meyka AI rates ALNA with a score out of 100: Score: 58.59 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst signals. Meyka AI’s forecast model projects a 12-month median price of $0.10, which implies +33.33% from the current price of USD 0.075. Forecasts are model-based projections and not guarantees.

Price targets and scenario analysis for ALNA stock

No formal analyst consensus is available, so we frame scenario targets for traders. Bear target $0.03 implies -60.00%, base target $0.10 implies +33.33%, and bull target $0.25 implies +233.33%. These targets reflect clinical risk, cash runway, and typical biotech volatility. Use these as reference points, not as investment advice.

Final Thoughts

ALNA stock is among the most active pre-market names on NASDAQ on 04 Feb 2026, trading at $0.075 with 252,311,606 shares reported. Short-term action is volume-driven and speculative, while fundamental metrics show a cash buffer of $0.92 per share and negative earnings. Meyka AI’s model projects a 12-month median of $0.10, implying +33.33% upside from USD 0.075, but the company carries typical early-stage biotech risks. Traders seeking exposure should weigh wide intraday swings, thin public float data, and the absence of recent analyst coverage. For real-time alerts and deeper metrics use our AI-powered market analysis platform at Meyka AI, and check regulatory news for clinical or financing updates before trading.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.